Results 21 to 30 of about 38,667 (276)

Incidences and factors associated with viral suppression or rebound among HIV patients on combination antiretroviral therapy from three counties in Kenya

International Journal of Infectious Diseases, 2020
Background: Limited data are available on the incidence and factors associated with viral rebound following viral suppression among HIV-infected individuals taking antiretroviral therapy (ART) in Kenya.
E.K. Maina, H. Mureithi, A.A. Adan, J. Muriuki, R.M. Lwembe, E.A. Bukusi   +5 more
doaj   +1 more source

Timing of initiation of anti-retroviral therapy predicts post-treatment control of SIV replication.

PLoS Pathogens, 2023
One approach to 'functional cure' of HIV infection is to induce durable control of HIV replication after the interruption of antiretroviral therapy (ART).
Mykola Pinkevych, Steffen S Docken, Afam A Okoye, Christine M Fennessey, Gregory Q Del Prete, Maria Pino, Justin L Harper, Michael R Betts, Mirko Paiardini, Brandon F Keele, Miles P Davenport   +10 more
doaj   +1 more source

Viral and Symptom Rebound in Untreated COVID-19 Infection

, 2022
SummaryBackgroundThere are reports of viral RNA and symptom rebound in people with COVID-19 treated with nirmatrelvir/ritonavir. Since the natural course of viral and symptom trajectories of COVID-19 has not been well described, we evaluated the incidence of viral and symptom rebound in untreated outpatients with mild-moderate COVID-19.MethodsThe study
Deo, Rinki, Choudhary, Manish C., Moser, Carlee, Ritz, Justin, Daar, Eric S., Wohl, David A., Greninger, Alexander L., Eron, Joseph J., Currier, Judith S., Hughes, Michael D., Smith, Davey M., Chew, Kara W., Li, Jonathan Z.   +12 more
openaire   +2 more sources

Potential biomarkers: Predicting post-treatment viral rebound in rhesus macaques

Cell Reports Medicine, 2023
In this issue of Cell Reports Medicine, Aid and colleagues define peripheral blood biomarkers, which predict viral rebound after antiretroviral therapy (ART) discontinuation in SIV-infected rhesus macaques treated early with ART, providing insights into potential HIV cure strategies.1.
Yang, Chenbo, Xue, Jing
openaire   +2 more sources

Models of SIV rebound after treatment interruption that involve multiple reactivation events

PLoS Computational Biology, 2020
In order to assess the efficacy of novel HIV-1 treatments leading to a functional cure, the time to viral rebound is frequently used as a surrogate endpoint. The longer the time to viral rebound, the more efficacious the therapy.
Christiaan H. van Dorp, Jessica M. Conway, Dan H. Barouch, James B. Whitney, Alan S. Perelson, Miles P. Davenport   +5 more
doaj   +2 more sources

Dynamics and origin of rebound viremia in SHIV-infected infant macaques following interruption of long-term ART

JCI Insight, 2021
Understanding viral rebound in pediatric HIV-1 infection may inform the development of alternatives to lifelong antiretroviral therapy (ART) to achieve viral remission.
Veronica Obregon-Perko, Katherine M. Bricker, Gloria Mensah, Ferzan Uddin, Laura Rotolo, Daryll Vanover, Yesha Desai, Philip J. Santangelo, Sherrie Jean, Jennifer S. Wood, Fawn C. Connor-Stroud, Stephanie Ehnert, Stella J. Berendam, Shan Liang, Thomas H. Vanderford, Katharine J. Bar, George M. Shaw, Guido Silvestri, Amit Kumar, Genevieve G. Fouda, Sallie R. Permar, Ann Chahroudi   +21 more
doaj   +1 more source

Viral suppression in HIV studies: Combining times to suppression and rebound [PDF]

Biometrics, 2014
SummaryIn HIV‐1 clinical trials the interest is often to compare how well treatments suppress the HIV‐1 RNA viral load. The current practice in statistical analysis of such trials is to define a single ad hoc composite event which combines information about both the viral load suppression and the subsequent viral rebound, and then analyze the data ...
Gouskova, Natalia A., Cole, Stephen R., Eron, Joseph J., Fine, Jason P.   +3 more
openaire   +2 more sources

Two-year follow-up of macaques developing intermittent control of the human immunodeficiency virus homolog simian immunodeficiency virus SIVmac251 in the chronic phase of infection [PDF]

, 2015
Off-therapy control of viremia by HIV-infected individuals has been associated with two likely players: a restricted viral reservoir and an efficient cell-mediated immune response.
Arts, Eric, Biffoni, Mauro, Chung, Hye Kyung, Farrell, Nicholas, Labranche, Celia, Lewis, Mark G., Montefiori, David, Nickel, Gabrielle, Pal, Ranajit, PALAMARA, ANNA TERESA, Robert Guroff, Marjorie, Sacha, Jonah B., Savarino, Andrea, Shytaj, Iart Luca, Vargas Inchaustegui, Diego   +14 more
core   +2 more sources

Highlights from the 24th conference on retroviruses and opportunistic infections, 13-16 February 2017, Seattle, Washington, USA [PDF]

, 2017
From the 13th to 16th February 2017, researchers from around the world convened for the 24th annual Conference on Retroviruses and Opportunistic Infections (CROI) at the Washington State Convention Center in Seattle, Washington.
Bhagani, Sanjay, Colby, Donn J, Crowell, Trevor A, Gathogo, Esther N, Hill, Andrew, Hsu, Denise, Kinloch, Sabine, Lyall, Hermione, Malatinková, Eva, Polyak, Christina, Psomas, Christina, Trypsteen, Wim, Vandekerckhove, Linos   +12 more
core   +8 more sources

Quantitative analysis of viral persistence and transient viral load rebound from HIV clinical data [PDF]

2011 Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2011
Highly active antiretroviral therapy (HAART) suppresses HIV RNA viral load below the limit of detection for many patients. However, clinical data demonstrates that the HIV virus is not eradicated by HAART, even in patients who have had no detectable virus for 7 years [1].
Rutao, Luo, Michael J, Piovoso, Ryan, Zurakowski   +2 more
openaire   +2 more sources